Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance

Biomaterials

Volumn 32, Issue 35, 2011, Pages 9444-9456

  Wang, Feihu ^a   Zhang, Dianrui ^a   Zhang, Qiang ^b   Chen, Yuxuan ^a   Zheng, Dandan ^a   Hao, Leilei ^a   Duan, Cunxian ^a   Jia, Lejiao ^a   Liu, Guangpu ^a   Liu, Yue ^a  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Drug efflux; Multidrug resistance; Paclitaxel; Polymeric micelles; Targeted delivery; Verapamil

Indexed keywords

DRUG EFFLUX; MULTIDRUG RESISTANCE; PACLITAXEL; POLYMERIC MICELLE; TARGETED DELIVERY; VERAPAMIL;

CELLS; CHEMOTHERAPY; GLYCOPROTEINS; POLYMERS; TUMORS;

MICELLES;

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; DEOXYCHOLIC ACID; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; FOLIC ACID; GLYCOPROTEIN P; LIPOCORTIN 5; PACLITAXEL; VERAPAMIL;

ARTICLE; CANCER RESISTANCE; CELL CYCLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG TUMOR LEVEL; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL NUCLEUS; CHITOSAN; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; FLUORESCENCE; FOLIC ACID; HUMANS; INHIBITORY CONCENTRATION 50; MICELLES; MICROSCOPY, ELECTRON, SCANNING; P-GLYCOPROTEIN; PACLITAXEL; PARTICLE SIZE; POLYMERS; VERAPAMIL; X-RAY DIFFRACTION;

EID: 80053609978     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.041     Document Type: Article

References (40)

1. Kim S.C., Kim D.W., Shim Y.H., Bang J.S., Oh H.S., Wan K.S., et al. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release 2001, 72:191-202.
2. Singla A.K., Garg A., Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002, 235:179-192.
3. Weiss R.B., Donehower R.C., Wiernik P.H. Hypersensitivity reactions from Taxol. J Clin Oncol 1990, 8:1263-1268.
4. Ho E.A., Soo P.L., Allen C., Piquette-Miller M. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors. J Control Release 2007, 117:20-27.
5. Krishnamachary N., Center M.S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993, 53:3658-3661.
6. Deffie A.M., Batra J.K., Goldenberg G.J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989, 49:58-62.
7. Zhang K., Mack P., Wong K.P. Glutathione-related mechanisms in cellular resistance to anticancer drugs. Int J Oncol 1998, 12:871-882.
8. Kirkin V., Joos S., Zornig M. The role of Bcl-2 family members in tumorigenesis. Biochim Biophys Acta 2004, 1644:229-249.
9. Viktorsson K., De Petris L., Lewensohn R. The role of p53 in treatment responses of lung cancer. Biochem Biophys Res Commun 2005, 331:868-880.
10. Mechetner E., Kyshtoobayeva A., Zonis S., Kim H., Stroup R., Garcia R., et al. Levels of multi-drug resistance (MDR1) P-glycoprotein expression by human breast cancer correlate with in vitro resistance to taxol and doxorubicin. Clin Cancer Res 1998, 4:389-398.
11. Rowinsky E.K., Donehower R.C. Paclitaxel (taxol). N Engl J Med 1995, 332:1004-1014.
12. Thomas H., Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003, 10:159-165.
13. Horton J.K., Thimmaiah K.N., Houghton J.A., Horowitz M.E., Houghton P.J. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts. Biochem Pharmacol 1989, 38:1727-1736.
14. Chavanpatil M.D., Patil Y., Panyam J. Susceptibility of nanoparticle-encapsulated paclitaxel to p-glycoprotein-mediated drug efflux. Int J Pharm 2006, 320:150-156.
15. Patil Y., Sadhukha T., Ma L., Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J Control Release 2009, 136:21-29.
16. Patil Y., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
17. Huang M., Liu-G T.I., Prat F., Centarti M., Sibille E. The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 1999, 135:97-105.
18. Ozofs R.F., Cunnion R.E., Kfecker R.W., Hamilton T.C., Ostchega Y., Parriflo J.E., et al. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 1987, 5:641-647.
19. Lee S.C., Kim C., Kwon I.C., Chung H., Jeong S.Y. Polymeric micelles of poly(2-ethyl-2-oxazoline)-block-poly(epsilon-caprolactone) copolymer as a carrier for paclitaxel. J Control Release 2003, 89:437-446.
20. Wang F.H., Zhang D.R., Duan C.X., Jia L.J., Feng F.F., Liu Y., et al. Preparation and characterizations of a Novel deoxycholic acid- O-carboxymethylated chitosan- folic acid conjugatesand self-aggregates. Carbohydr Polym 2011, 84:1192-1200.
21. Zhang C., Qineng P., Zhang H. Self-assembly and characterization of paclitaxel-loaded N-octyl-O-sulfate chitosan micellar system. Colloids Surf B 2004, 39:69-75.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63.
23. Seow W.Y., Xue J.M., Yang Y.Y. Targeted and intracellular delivery of paclitaxel using multi-functional polymeric micelles. Biomaterials 2007, 28:1730-1740.
24. Mahmud A., Xiong X.B., Aliabadi H.M., Lavasanifar A. Polymeric micelles for drug targeting. J Drug Target 2007, 15:553-584.
25. Kim K., Kwon S., Hyung Park J., Chung H., Young Jeon S. Physicochemical characteristics of self-assembled nanoparticles based on glycol chitosan bearing 5β-cholanic acid. Langmuir 2003, 19:10188-10193.
26. Müller R.H., Jacobs C. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. Int J Pharm 2002, 237:151-161.
27. Raghunand N., He X., van Sluis R., Mahoney B., Baggett B., Taylor C.W., et al. Enhancement of chemotherapy by manipulation of tumor pH. Br J Cancer 1999, 80:1005-1011.
28. Lee E.S., Na K., Bae Y.H. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. J Control Release 2005, 103:405-418.
29. Vredenburg R.M., Ojima I., Veith J., Pera P., Kee K., Cabral F., et al. Effects of orally active taxanes on P-glycoprotein modulation and colon and breast carcinoma drug resistance. J Natl Cancer Inst 2001, 93:1234-1245.
30. Krishna R., Mayer L.D. Multidrug resistance (MDR) in cancer: mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11:265-283.
31. Wang Y.Z., Yu L., Han L.M., Sha X.Y., Fang X.L. Difunctional Pluronic copolymer micelles for paclitaxel delivery: synergistic effect of folate-mediated targeting and Pluronic-mediated overcoming multidrug resistance in tumor cell lines. Int J Pharm 2007, 337:63-73.
32. Park K. All nanocarriers are created equal. J Control Release 2008, 130:139.
33. Mansouri S., Cuie Y., Winnik F., Shi Q., Lavigne P. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials 2006, 27:2060-2065.
34. Park E.K., Lee S.B., Lee Y.M. Preparation and characterization of methoxy poly(ethylene glycol)/poly(e-caprolactone) amphiphilic block copolymeric nanospheres for tumorspecific folate-mediated targeting of anticancer drugs. Biomaterials 2005, 26:1053-1061.
35. Liu S.Q., Wiradharma N., Gao S.J., Tong Y.W., Yang Y.Y. Bio-functional micelles self-assembled from a folate-conjugated block copolymer for targeted intracellular delivery of anticancer drugs. Biomaterials 2007, 28:1423-1433.
36. Kabanov A.V., Batrakova E.V., Alakhov V.Y. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002, 54:759-779.
37. Adcock I.M., Ito K. Glucocorticoid pathways in chronic obstructive pulmonary disease therapy. Proc Am Thorac Soc 2005, 2:313-319.
38. Zhao J., Kim J.E., Reed E., Li Q.Q. Molecular mechanism of antitumor activity of taxanes in lung cancer (review). Int J Oncol 2005, 27:247-256.
39. Soma C.E., Dubernet C., Bentolila D., Benita S., Couvreur P. Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nanoparticles. Biomaterials 2000, 21:1-7.
40. Wang J., He F.T., Tzang C.H., Fong W.F., Xiao P.G., Han R., et al. Differential gene expression profiles in paclitaxel-induced cell cycle arrest and apoptosis in human breast cancer MCF-7 cells. Yao Xue Xue Bao 2005, 40:1099-1104.